About: “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
Creator	Chouchana, Laurent Drici, Milou-Daniel Fresse, Audrey Granvuillemin, Aurélie Gérard, Alexandre Parassol, Nadège Rocher, Fanny Romani, Serena Viard, Delphine
Source	Elsevier; Medline; PMC
abstract	Summary Introduction: COVID-19 is an unprecedented challenge for physicians and scientists. Several publicized drugs are being used with not much evidence of their efficacy such as hydroxychloroquine, azithromycin or lopinavir-ritonavir. Yet, the cardiac safety of these drugs in COVID-19 deserves scrutiny as they are known to foster cardiac adverse ADRs, notably QTc interval prolongation on the electrocardiogram and its arrhythmogenic consequences. Methods: Since March 27th, 2020, the French Pharmacovigilance Network directed all cardiac adverse drug reactions associated with “off-label” use of hydroxychloroquine, azithromycin and lopinavir-ritonavir in COVID-19 to the Nice Regional Center of Pharmacovigilance. Each Regional Center of Pharmacovigilance first assessed causality of drugs. We performed a specific analysis of these cardiac adverse drug reactions amidst an array of risk factors, reassessed the electrocardiograms and estimated their incidence in coronavirus-disease-2019. Results: In one month, 120 reports of cardiac adverse drug reactions have been notified, 102 of which associated with hydroxychloroquine alone (85%), or associated with azithromycin (60%). Their estimated incidence is 0.77% to 1.54% of all patients, notwithstanding strong underreporting. Lopinavir-ritonavir came third with 17 reports (14%) and chloroquine fourth with 3 reports (2.5%). There were 8 sudden, unexplained or aborted deaths (7%), 8 ventricular arrhythmias (7 %), 90 reports of prolonged QTc (75%) most of them “serious” (64%), 48 of which proved ≥ 500 ms, 20 reports of severe conduction disorders (17%) and 5 reports of other cardiac causes (4%). Six reports derived from automedication. Discussion and conclusion: “Off-label” use of treatments in COVID-19 increases the risk of cardiac ADRs, some of them avoidable. Even if these drugs are perceived as familiar, they are used in patients with added risk factors caused by infection. Precautions should be taken to mitigate the risk, even if they will be proven efficacious.
has issue date	2020-05-07(xsd:dateTime)
bibo:doi	10.1016/j.therap.2020.05.002
bibo:pmid	32418730
has license	els-covid
sha1sum (hex)	2cbd0d0f17cad7dd86798c201b8d36b3e489503e
schema:url	https://doi.org/10.1016/j.therap.2020.05.002
resource representing a document's title	“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
has PubMed Central identifier	PMC7204701
has PubMed identifier	32418730
schema:publication	Therapie
resource representing a document's body	covid:2cbd0d0f17cad7dd86798c201b8d36b3e489503e#body_text
is schema:about of	named entity 'Off-label' named entity 'chloroquine' named entity 'chloroquine' named entity 'ritonavir' named entity 'Pharmacovigilance' named entity 'chloroquine' named entity 'lopinavir' named entity 'Off-label' named entity 'COVID-19' named entity 'hydroxychloroquine' named entity 'azithromycin' named entity 'chloroquine' named entity 'cardiac arrest' named entity 'coronavirus 2' named entity 'QTc' named entity 'ventricular arrhythmias' named entity 'chloroquine' named entity 'April 27' named entity 'pharmacovigilance' named entity 'vaccine' named entity 'asthmatic' named entity 'COVID' named entity 'QTc' named entity 'antiviral' named entity 'COVID' named entity 'potassium' named entity 'ventricular arrhythmias' named entity 'infection' named entity 'Pharmacovigilance' named entity 'health professional' named entity 'ADRs' named entity 'potassium channel' named entity 'kalemia' named entity 'QTc' named entity 'bradycardia' named entity 'LOPI' named entity 'diarrhea' named entity 'safety profile' named entity 'diffusion' named entity 'life-threatening' named entity 'QTc' named entity 'Cardiac action potential' named entity 'HCQ' named entity 'France' named entity 'QT interval' named entity 'ECGs' named entity 'PhD' named entity 'COVID-19' named entity 'QTc' named entity 'ECG monitoring' named entity 'pharmacovigilance' named entity 'Descriptive statistics' named entity 'electrolyte disturbances' named entity 'pulmonary complications' named entity 'HCQ' named entity 'IKr' named entity 'Medical Pharmacology' named entity 'IKr' named entity 'pharmacovigilance' named entity 'overdosage' named entity 'QT interval' named entity 'QTc prolongation' named entity 'health professionals' named entity 'torsades de pointes' named entity 'tablets' named entity 'ECGs' named entity 'HCQ' named entity 'HCQ' named entity 'prolong the QT interval' named entity 'QTc' named entity 'rhythm disorders' named entity 'QT prolongation' named entity 'escitalopram'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software